In the latest session, Kura Oncology Inc (NASDAQ: KURA) closed at $6.2 down -0.56% from its previous closing price of $6.23. In other words, the price has decreased by -$0.56 from its previous closing price. On the day, 0.89 million shares were traded. KURA stock price reached its highest trading level at $6.41 during the session, while it also had its lowest trading level at $6.19.
Ratios:
For a deeper understanding of Kura Oncology Inc’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 0.81 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 4.85. For the most recent quarter (mrq), Quick Ratio is recorded 8.07 and its Current Ratio is at 8.07. In the meantime, Its Debt-to-Equity ratio is 0.05 whereas as Long-Term Debt/Eq ratio is at 0.04.
On October 24, 2024, UBS started tracking the stock assigning a Buy rating and target price of $27.
Stifel Downgraded its Buy to Hold on October 14, 2024, whereas the target price for the stock was revised from $26 to $19.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on May 19 ’25 when Bair Teresa Brophy sold 1,559 shares for $5.96 per share. The transaction valued at 9,292 led to the insider holds 107,948 shares of the business.
FORD KATHLEEN sold 1,558 shares of KURA for $9,777 on May 19 ’25. The Chief Operating Officer now owns 21,367 shares after completing the transaction at $6.28 per share. On May 19 ’25, another insider, FORD KATHLEEN, who serves as the Officer of the company, bought 1,558 shares for $5.96 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, KURA now has a Market Capitalization of 536330304 and an Enterprise Value of -99476696. For the stock, the TTM Price-to-Sale (P/S) ratio is 7.89 while its Price-to-Book (P/B) ratio in mrq is 1.37. Its current Enterprise Value per Revenue stands at -1.463 whereas that against EBITDA is 0.491.
Stock Price History:
The Beta on a monthly basis for KURA is 0.41, which has changed by -0.7007246 over the last 52 weeks, in comparison to a change of 0.17535925 over the same period for the S&P500. Over the past 52 weeks, KURA has reached a high of $21.60, while it has fallen to a 52-week low of $5.41. The 50-Day Moving Average of the stock is 0.36%, while the 200-Day Moving Average is calculated to be -30.95%.
Shares Statistics:
For the past three months, KURA has traded an average of 1.29M shares per day and 1278960 over the past ten days. A total of 86.57M shares are outstanding, with a floating share count of 82.28M. Insiders hold about 4.96% of the company’s shares, while institutions hold 89.96% stake in the company. Shares short for KURA as of 1752537600 were 8406094 with a Short Ratio of 6.54, compared to 1749772800 on 7896747. Therefore, it implies a Short% of Shares Outstanding of 8406094 and a Short% of Float of 9.729999.
Earnings Estimates
The dynamic stock of Kura Oncology Inc (KURA) is currently being evaluated by a team of 10.0 analysts, each contributing to its current rating.The consensus estimate for the next quarter is -$0.64, with high estimates of $0.15 and low estimates of -$0.89.
Analysts are recommending an EPS of between -$0.14 and -$3.3 for the fiscal current year, implying an average EPS of -$2.06. EPS for the following year is -$1.95, with 10.0 analysts recommending between $0.88 and -$4.82.
Revenue Estimates
A total of 13 analysts have provided revenue estimates for KURA’s current fiscal year. The highest revenue estimate was $438.6M, while the lowest revenue estimate was $19.31M, resulting in an average revenue estimate of $161.42M. In the same quarter a year ago, actual revenue was $53.88MBased on 14 analysts’ estimates, the company’s revenue will be $204M in the next fiscal year. The high estimate is $451.2M and the low estimate is $20.05M.
